

=> d his ful

(FILE 'HOME' ENTERED AT 16:37:38 ON 08 AUG 2003)

FILE 'REGISTRY' ENTERED AT 16:48:02 ON 08 AUG 2003

L14	STR
L15	6 SEA SSS SAM L14
L16	SCREEN 2021
L17	116 SEA SSS FUL L14 NOT L16
L18	113 SEA ABB=ON L17 AND NR<6
L19	113 SEA ABB=ON L18 AND NRS<6

FILE 'HCAPLUS' ENTERED AT 17:01:48 ON 08 AUG 2003

2 SEA ABB=ON L19

2 cits for generic structure L14 - see d one stat,
attached. These 2 cits are included herewith.

FILE 'REGISTRY' ENTERED AT 17:10:06 ON 08 AUG 2003

L21	STR L14
L22	1 SEA SSS SAM L21
L23	27 SEA SSS FUL L21
L24	STR L21
L25	0 SEA SSS SAM L24
L26	2 SEA SSS FUL L24
L27	STR L21
L28	0 SEA SSS SAM L27
L29	0 SEA SSS FUL L27
L30	STR L27
L31	0 SEA SSS SAM L30
L32	0 SEA SSS FUL L30
L33	STR L21
L34	0 SEA SSS SAM L33
L35	0 SEA SSS FUL L33
L36	STR L33
L37	0 SEA SSS SAM L36
L38	0 SEA SSS FUL L36
L39	STR L36
L40	0 SEA SSS SAM L39
L41	0 SEA SSS FUL L39
L42	2 SEA ABB=ON (393580-25-1 OR 393580-84-2) /RN

Pls. see attached d one stat's keyed
to the structures you furnished.

Str. ① was located among these 27, &
RN searched - see below.

Str. 26 - was one of these 2

>st for 36 - no hits

) st for 3a - no hits

str. ①

str. 26

FILE 'HCAPLUS' ENTERED AT 17:45:47 ON 08 AUG 2003

1 SEA ABB=ON L42

1 cit. for str. 14 26

FILE 'REGISTRY' ENTERED AT 18:17:04 ON 08 AUG 2003

1 SEA ABB=ON 393580-82-0/RN

str. 2a - located by manual examination of L20
cits.

FILE 'HCAPLUS' ENTERED AT 18:17:22 ON 08 AUG 2003

1 SEA ABB=ON L44

1 SEA ABB=ON L43 OR L44

The same cit. for str. 2a

This cit. was included here

L43

L44

L45

L46


Genetic structure

Mondesi 09/909,012

08/08/2003

=> d que stat 120

L14 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 38

STEREO ATTRIBUTES: NONE

L16 SCR 2021

L17 116 SEA FILE=REGISTRY SSS FUL L14 NOT L16

L18 113 SEA FILE=REGISTRY ABB=ON L17 AND NR<6

L19 113 SEA FILE=REGISTRY ABB=ON L18 AND NRS<6


→ L20 2 SEA FILE=HCAPLUS ABB=ON L19 *2 out*

Structure for compd. ①

Mondesi 09/909, 012

08/08/2003

=> d que stat 121
L21 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 44


STEREO ATTRIBUTES: NONE

Structure for 2b

Mondesi 09/909,012

08/08/2003

=> d que stat 124
L24 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 50


STEREO ATTRIBUTES: NONE

Structure for 3a

Mondesi 09/909, 012

08/08/2003

=> d que stat 139
L39 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED
NUMBER OF NODES IS 53


STEREO ATTRIBUTES: NONE

Structure for 3b

Mondesi 09/909,012

08/08/2003

=> d que stat 133
L33 STR



NODE ATTRIBUTES:

DEFAULT MLEVEL IS ATOM

DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:

RING(S) ARE ISOLATED OR EMBEDDED

NUMBER OF NODES IS 53

STEREO ATTRIBUTES: NONE



Mondesi 09/909,012

08/08/2003

=> d ibib abs hitstr 120 1-2

L20 ANSWER 1 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:466030 HCAPLUS
DOCUMENT NUMBER: 137:47444
TITLE: Preparation of diaryl peptides as NS3-serine protease
inhibitors of hepatitis C virus
INVENTOR(S): Zhu, Zhaoning; Sun, Zhong-Yue; Venkatraman, Srikanth;
Njoroge, F. George; Arasappan, Ashok; Malcolm, Bruce
A.; Girijavallabhan, Viyyoor M.; Lovey, Raymond G.;
Chen, Kevin X.
PATENT ASSIGNEE(S): Schering Corporation, USA
SOURCE: PCT Int. Appl., 149 pp.
DOCUMENT TYPE: CODEN: PIXXD2
LANGUAGE: Patent
FAMILY ACC. NUM. COUNT: English 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002048172	A2	20020620	WO 2001-US47383	20011210
WO 2002048172	A3	20030619		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UZ, VN, YU, ZA, ZM, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2002036591	A5	20020624	AU 2002-36591	20011210
US 2002147139	A1	20021010	US 2001-13071	20011210
PRIORITY APPLN. INFO.: US 2000-254869P P 20001212				
OTHER SOURCE(S): MARPAT 137:47444 W 20011210 GI				



AB Title compds. I [X, Y = (cyclo)alkyl, heteroalkyl, (aryl)heteroaryl, alkyl(hetero)aryl, substituted ether, sulfide, sulfone, amide, sulfonamide, urea, carbamate, hydrazide, carbonyl, etc.; W = null, CO, CS, or SO₂; Q = null, CH, N, P, alkylene, O, imino, S, or SO₂; A = O, CH₂, alkylene, imino, S, SO₂, or a bond; E = CH or substituted methylidyne, N, or a double bond toward A, L, or G; G = null or alkylene; J = null or alkylene, SO₂, imino, or O; L = null or CH or substituted methylidyne, O, S, or imino; M = null or O, imino, S, SO₂, or alkylene; P_{1a}, P_{1b}, P_{1'}, P₃ = H, alkyl, alkenyl, cycloalkyl, heterocyclyl, (cycloalkyl)alkyl, or (heterocyclyl)alkyl; P_{1a}P_{1b}C may form a ring; Z = O or imino; Ar₁, Ar₂ = (un)substituted Ph, 2-, 3-, or 4-pyridyl or their N-oxides, 2- or 3-furanyl, etc.; P₄ = H, alkyl, arylalkyl, or aryl; R₂ = H, cyano, CF₃, (cyclo)alkyl, aryl, carboxy, etc. (with provisos)] were prepd. as hepatitis C virus (HCV) protease inhibitors. Thus, compd. II was prepd. by a multi-step procedure and showed Ki = 100-999 nM for inhibition of serine protease.

IT 393580-15-9P 437768-31-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of diaryl peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393580-15-9 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX)


Absolute stereochemistry.



RN 437768-31-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L20 ANSWER 2 OF 2 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002-00005

ACCESSION NUMBER: 2002:90007 HCAPLUS
DOCUMENT NUMBER: 136:151439
TITLE:

TITLE: Preparation

INVENTOR(S): Saksena, Anil K.; Saksena, Meenakshi
Preparation of novel peptides as NS3-serine protease inhibitors of hepatitis C virus

INVENTOR(S): Inhibitors of hepatitis C virus
Saksema, Anil K.; Girijavallabhan, Viyyoor Moopil;
Bogen, Stephane L.; Lovey, Raymond G.; Jao, Edwin E.;
Bennett, Frank; McCormick, Jinping L.; Wang, Haiyan;
Pike, Russell E.; Liu, Yi-Tsung; Chan, Tin-Yau; Zhu,
Zhaoning; Arasappan, Ashok; Chen, Kevin X.;
Venkatraman, Srikanth; Parekh, Tejal N.; Pinto,
Patrick A.; Santhanam, Bama; Njoroge, F. George;
Ganguly, Ashit K.; Vaccaro, Henry A.; Kemp, Scott
Jeffrey; Levy, Odile Esther; Lim-Wilby, Marguerita;
Tamura, Susan Y.

PATENT ASSIGNEE(S):

SOURCE:

DOCUMENT TYPE:



**DOCUMENT
LANGUAGE:**

B
A
N
G
U
A
G
E : English
F
A
M
I
L
Y
A
C
C
G
N
U
M
S
C
O
M
P
T

FAMILY ACC. NUM. CO
PATENT INFORMATION

Searched by Mary Jane Ruhl 605-1155

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008187	A1	20020131	WO 2001-US22813	20010719
WO 2002008187	C2	20030103		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2002160962	A1	20021031	US 2001-909012	20010719
EP 1303487	A1	20030423	EP 2001-959041	20010719
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
BR 2001012666	A	20030610	BR 2001-12666	20010719
NO 2003000271	A	20030318	NO 2003-271	20030120
PRIORITY APPLN. INFO.:				
US 2000-220107P P 20000721				
WO 2001-US22813 W 20010719				
OTHER SOURCE(S): MARPAT 136:151439				
GI				



AB Novel peptides I [G, J, Y = independently H, alkyl, alkyl-aryl, heteroalkyl, heteroaryl, aryl-heteroaryl, alkyl-heteroaryl, cycloalkyl, alkoxy, alkyl-aryloxy, aryloxy, heteroaryloxy, heterocycloalkyloxy, cycloalkyloxy, alkylamino, arylamino, alkyl-aryl amino, arylamino, heteroaryl amino, cycloalkylamino, and heterocycloalkylamino; Z = O, N, CH; W = null, CO, CS, SO₂; R1 = COR5, B(OR)2; R5 = H, OH, OR8, NR9R10, CF3, C2F5, C3F7, CF2R6, R6, COR7; R7 = H, OH, OR8, CHR9R10, NR9R10; R6, R8-10 = independently H, alkyl, aryl, heteroalkyl, cycloalkyl, arylalkyl, peptide deriv., etc.; R, R2-4 = independently H, alkyl, alkenyl, cycloalkyl, heterocycloalkyl, alkoxy, aryloxy, alkylthio, arylthio, amino, amido,

08/08/2003

ester, carboxylic acid, carbamate, etc.] and their pharmaceutically salts which have hepatitis C virus (HCV) protease inhibitory activity were prepd. via soln. or solid-phase peptide coupling methods. Thus, peptide II was prepd. using solid-phase methods and showed a Ki value in the range of 0-100 nM for HCV protease inhibitory activity. This invention also discloses pharmaceutical compns. comprising such compds. as well as methods of using them to treat disorders assocd. with the HCV protease.

IT 393580-04-6P 393580-05-7P 393580-06-8P
 393580-07-9P 393580-08-0P 393580-09-1P
 393580-10-4P 393580-11-5P 393580-12-6P
 393580-13-7P 393580-15-9P 393580-16-0P
 393580-17-1P 393580-18-2P 393580-19-3P
 393580-20-6P 393580-21-7P 393580-22-8P
 393580-23-9P 393580-25-1P 393580-26-2P
 393580-27-3P 393580-28-4P 393580-30-8P
 393580-31-9P 393580-40-0P 393580-41-1P
 393580-52-4P 393580-54-6P 393580-55-7P
 393580-56-8P 393580-59-1P 393580-60-4P
 393580-61-5P 393580-79-5P 393580-80-8P
 393580-81-9P 393580-82-0P 393580-83-1P
 393580-84-2P 393580-85-3P 393580-86-4P
 393580-87-5P 393580-89-7P 393580-92-2P
 393580-93-3P 393580-97-7P 393581-00-5P
 393581-01-6P 393581-02-7P 393581-03-8P
 393581-04-9P 393581-05-0P 393581-06-1P
 393581-07-2P 393581-11-8P 393581-12-9P
 393581-13-0P 393581-14-1P 393581-15-2P
 393581-16-3P 393581-17-4P 393581-18-5P
 393581-19-6P 393581-20-9P 393581-77-6P
 393582-01-9P 393582-02-0P 393582-03-1P
 393582-04-2P 393582-05-3P 393582-06-4P
 393582-07-5P 393582-08-6P 393582-12-2P
 393582-13-3P 393582-14-4P 393582-16-6P
 393582-17-7P 393582-18-8P 393582-26-8P
 393582-28-0P 393582-30-4P 393582-31-5P
 393582-32-6P 393582-33-7P 393582-34-8P
 393582-35-9P 393582-36-0P 393582-37-1P
 393582-38-2P 393582-39-3P 393582-40-6P
 393582-45-1P 393582-51-9P 393582-52-0P
 393582-53-1P 393582-54-2P 393582-55-3P
 393582-57-5P 393582-58-6P 393817-40-8P
 394203-62-4P 394203-63-5P 394203-64-6P
 394203-75-9P 394203-76-0P 394203-77-1P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393580-04-6 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(4-pentylbicyclo[2.2.2]oct-1-yl)oxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-05-7 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(tricyclo[3.3.1.13,7]dec-1-ylmethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-06-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-(.alpha.S)-.alpha.-aminobenzenebutanoyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-07-9 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-08-0 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-4-bromo-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-09-1 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5,5-trifluoro-2-oxopentanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-10-4 HCAPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxo-3-phenylpropyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(phenylmethyl) ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-11-5 HCPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxo-3-phenylpropyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-12-6 HCPLUS

CN Glycine, (2S)-N-(4-carboxy-1-oxo-4-phenylbutyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 5-(phenylmethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

Ph

RN 393580-13-7 HCPLUS

CN Glycine, (2S)-N-(4-carboxy-1-oxo-4-phenylbutyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-15-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2,2-diphenyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-16-0 HCAPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-4-fluoro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-17-1 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-chloro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-18-2 HCAPLUS
 CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4-fluoro-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-19-3 HCAPLUS
 CN Glycine, (2S)-N-(3-carboxy-1-oxo-5-heptenyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.
 Double bond geometry unknown.



RN 393580-20-6 HCPLUS

CN Glycine, (2S)-N-(3-carboxy-1-oxoheptyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-21-7 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N-cyclohexyl-2-(4-phenoxyphenyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Mondesi 09/909,012

08/08/2003

RN 393580-22-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N-cyclohexyl-2-(4-ethoxyphenyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393580-23-9 HCAPLUS

CN Glycine, (2S)-N-acetyl-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(4-phenoxyphenyl)glycyl-, methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-25-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoyl-2-13C-glycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-26-2 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoyl-2-¹³C-glycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-27-3 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Mondesi 09/909, 012

08/08/2003

RN 393580-28-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-30-8 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-[1,1'-biphenyl]-4-yl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-31-9 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-40-0 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(2-fluorophenyl)-, methyl ester, (2R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-41-1 HCPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-(2-fluorophenyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-52-4 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-54-6 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-55-7 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxolan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393580-56-8 HCPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxolan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-59-1 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-60-4 HCPLUS

CN Glycine, (2S)-N-(2-aminobenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-61-5 HCPLUS


CN Glycine, (2S)-2-cyclohexyl-N-(2-hydroxybenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393580-79-5 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-.alpha.-amino oxiranepropanoyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-80-8 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-dihydroxynorvalyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393580-81-9 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-82-0 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydronorvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393580-83-1 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-84-2 HCPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydronorvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393580-85-3 HCAPLUS

CN Glycine, (2S)-N-[3-carboxy-5-(1,1-dimethylethyl)benzoyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-86-4 HCAPLUS

CN Glycine, (2S)-N-[4-(carboxymethyl)-5,5-dimethyl-1-oxohexyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-87-5 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-(4-fluorobenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393580-89-7 HCAPLUS


CN Glycine, (2S)-N-[2-(4-chlorophenyl)-2-methyl-1-oxopropyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393580-92-2 HCAPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, methyl ester (9CI) (CA INDEX NAME)



RN 393580-93-3 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-

phenyl- (9CI) (CA INDEX NAME)




RN 393580-97-7 HCAPLUS

CN Glycine, .alpha.-hydroxybenzeneacetyl-2-cyclohexylglycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-00-5 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-01-6 HCAPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-

methoxy-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-02-7 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393581-03-8 HCPLUS


CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (9CI) (CA INDEX NAME)



RN 393581-04-9 HCPLUS


CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-

oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX
NAME)




RN 393581-05-0 HCPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-(1,1-dimethylethyl)-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-06-1 HCPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-N-methylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-07-2 HCPLUS

CN Glycinamide, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropylalanyl-beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-11-8 HCAPLUS

CN Glycine, N-[(2-butynyloxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropylalanyl-beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)



RN 393581-12-9 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-propynyloxy)carbonyl]glycyl-3-cyclopropylalanyl-beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-13-0 HCAPLUS

Mondesi 09/909,012


08/08/2003

CN Glycine, 2-cyclohexyl-N-[(4,4-dimethyl-2-pentynyl)oxy]carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-14-1 HCPLUS

CN Glycine, 2-cyclohexyl-N-[(2-propynyloxy)carbonyl]glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-15-2 HCPLUS

CN Glycine, N-[(2-butynyloxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)




RN 393581-16-3 HCPLUS

Mondesi 09/909.012

08/08/2003

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-N-methyl-L-leucyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393581-17-4 HCAPLUS


CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-N-methyl-L-phenylalanyl-3-amino-2-oxohexanoylglycyl-N,N-dimethyl-2-phenyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393581-18-5 HC APIUS

CN Glycine, 2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-19-6 HCAPLUS

Mondesi 09/909, 012


08/08/2003

CN Glycine, 2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)



RN 393581-20-9 HCPLUS

CN Glycine, 2-cyclohexyl-N-(2-hydroxybenzoyl)glycyl-3-cyclopropylalanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 393581-77-6 HCPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-(3S)-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


08/08/2003



RN 393582-01-9 HCAPLUS

CN Glycine, (2S)-N-[(4-(carboxymethyl)phenyl)acetyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-02-0 HCAPLUS

CN Glycine, (2S)-N-[[3-(carboxymethyl)phenyl]acetyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-L-phenyl (2S)-[2S]-


Absolute stereochemistry



RN 393582-03-1 HCABRIUS

RI 555502-03-1 HCAPLUS
CN Glycine, (2S)-N-(4-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-04-2 HCPLUS

CN Glycine, (2S)-N-(3-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-05-3 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(cyclohexyloxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-06-4 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[4-(methoxycarbonyl)phenoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-07-5 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(3-methoxy-2,2-dimethyl-3-oxopropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-08-6 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-12-2 HCPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3-methylbenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-13-3 HCPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-14-4 HCPLUS

CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-16-6 HCPLUS

CN Glycinamide, (2S)-N-[{(2-carboxy-1-cyclopenten-1-yl)carbonyl}-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl], (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-17-7 HCPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3-hydroxybenzoyl)-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-18-8 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(2,3,4,5,6-pentafluorobenzoyl)glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




Mondesi 09/909,012

08/08/2003

RN 393582-26-8 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(tetrahydro-3-furanyl)methoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-28-0 HCAPLUS

CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-L-leucyl-3-amino-5-methyl-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-30-4 HCAPLUS

CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-cyclopropyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-31-5 HCAPLUS

CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxolan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-32-6 HCAPLUS

CN Glycine, (2S)-N-[(2-methylpropoxy)carbonyl]-2-phenylglycyl-3-(1,3-dioxan-2-yl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-33-7 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-34-8 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-35-9 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-36-0 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N-methoxy-N-methyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-37-1 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-N,N-dimethyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-38-2 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-, 1,1-dimethylethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-39-3 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-4,5-didehydro-L-norvalyl-3-amino-2-oxo-5-hexenoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-40-6 HCAPLUS

CN Glycine, (2S)-N-[3-(2-carboxyethyl)-4,4-dimethyl-1-oxopentyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-45-1 HCAPLUS

CN Glycine, (.alpha.S)-.alpha.-hydroxybenzeneacetyl-(2S)-2-cyclohexylglycyl-3-phenyl-, (2S)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-51-9 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(4,4-dimethyl-2-pentynyl)oxy]carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-52-0 HCPLUS


CN Glycine, (2S)-2-cyclohexyl-N-[(2-propynyoxy)carbonyl]glycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-53-1 HCAPLUS
 CN Glycine, (2S)-N-[(2-butynyoxy)carbonyl]-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393582-54-2 HCAPLUS
 CN Glycinamide, (2S)-N-(2-carboxybenzoyl)-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393582-55-3 HCAPLUS
 CN Glycinamide, (2S)-N-(3-carboxybenzoyl)-2-cyclohexylglycyl-3-cyclopropyl-L-alanyl-.beta.-amino-.alpha.-oxocyclopropanebutanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393582-57-5 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-cyclobutyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.




RN 393582-58-6 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-O-phenyl-L-homoseryl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393817-40-8 HCAPLUS

CN Glycine, 2-cyclohexyl-N-[(2-methylpropoxy)carbonyl]glycyl-3-(1,3-dioxan-2-yl)alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)

RN 394203-62-4 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(3-methylbicyclo[2.2.1]hept-2-yl)methoxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-,
(2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-63-5 HCAPLUS

CN Glycine, (2S)-N-[(3-carboxybicyclo[2.2.1]hept-2-yl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)-
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-64-6 HCPLUS

CN Glycine, (2S)-N-[(3-carboxybicyclo[2.2.1]hept-5-en-2-yl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-75-9 HCPLUS

CN Glycine, (2S)-N-[(4-carboxycyclohexyl)carbonyl]-2-cyclohexylglycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 394203-76-0 HCPLUS


CN Glycine, (2S)-N-[(3-carboxycyclohexyl)carbonyl]-2-cyclohexylglycyl-L-

Mondesi 09/909,012

08/08/2003

leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 394203-77-1 HCPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[[[4-(ethoxycarbonyl)cyclohexyl]oxy]carbonyl]glycyl-L-leucyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 393581-45-8P 393581-59-4P 393581-64-1P

393581-69-6P 393581-77-6DP, resin-bound


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393581-45-8 HCPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-(2-naphthalenyl)-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-59-4 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-1-[(phenylmethoxy)carbonyl]-L-histidyl-3-amino-2-oxohexanoylglycyl-2-phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-64-1 HCAPLUS

CN Glycine, (2S)-2-cyclohexyl-N-[(1,1-dimethylethoxy)carbonyl]glycyl-3-[(5,6,7,8-tetrahydro-1-naphthalenyl)carbonyl]-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenylmethyl ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-69-6 HCAPLUS

CN Glycinamide, (2S)-2-cyclohexyl-N-(phenylacetyl)glycyl-3-cyclopropyl-L-alanyl-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393581-77-6 HCAPLUS

CN Glycinamide, (2S)-N-(2-carboxy-3,6-difluorobenzoyl)-2-cyclohexylglycyl-L-leucyl-(3S)-3-amino-2-oxohexanoylglycyl-2-phenyl-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



Mondesi 09/909,012

08/08/2003

REFERENCE COUNT:

3

THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Inventor Search



Mondesi 09/909,012

08/08/2003

=> d ibib abs hitstr 113 1-1

L13 ANSWER 1 OF 1 HCAPLUS COPYRIGHT 2003 ACS on STN
ACCESSION NUMBER: 2002:90074 HCAPLUS
DOCUMENT NUMBER: 136:151440
TITLE: Preparation of novel peptides as NS3-serine protease
inhibitors of hepatitis C virus
INVENTOR(S): Saksena, Anil K.; Girijavallabhan,
Viyyoor Moopil; Lovey, Raymond G.; Jao,
Edwin E.; Bennett, Frank;
McCormick, Jinping; Wang, Haiyan; Pike,
Russell E.; Bogen, Stephane L.; Liu,
Yi-Tsung; Arasappan, Ashok; Parekh, Tejal; Pinto,
Patrick A.; Njoroge, F. George; Ganguly, Ashit K.;
Brunck, Terence K.; Kemp, Scott Jeffrey; Levy, Odile
Esther; Lim-Wilby, Marguerita
PATENT ASSIGNEE(S): Schering Corporation, USA; Corvas International, Inc.
SOURCE: PCT Int. Appl., 197 pp.
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002008256	A2	20020131	WO 2001-US22826	20010719
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, HR, HU, ID, IL, IN, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LU, LV, MA, MD, MG, MK, MN, MX, MZ, NO, NZ, PL, PT, RO, RU, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UZ, VN, YU, ZA, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
US 2003036501	A1	20030220	US 2001-909062	20010719
EP 1301528	A2	20030416	EP 2001-959046	20010719
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
PRIORITY APPLN. INFO.:			US 2000-220109P	P 20000721
OTHER SOURCE(S):	MARPAT 136:151440		WO 2001-US22826	W 20010719
GI				



AB Novel peptides I [Z = O, NH or substituted imino; X = (un)substituted alkylsulfonyl, heterocyclsulfonyl, heterocyclalkylsulfonyl, arylsulfonyl, heteroarylsulfonyl, alkylcarbonyl, heterocyclcarbonyl, heterocyclalkylcarbonyl, arylcarbonyl, heteroarylcarbonyl, alkoxy carbonyl, heterocyclloxycarbonyl, aryloxycarbonyl, heteroaryloxycarbonyl, alkyaminocarbonyl, heterocyclaminocarbonyl, arylaminocarbonyl, or heteroarylaminocarbonyl; X1 = H, alkyl, arylmethyl, P1a, P1b, P2-P6 = H, (un)substituted alkyl, alkenyl, cycloalkyl, heterocycl, cycloalkylalkyl, heterocyclalkyl, aryl, heteroaryl, arylalkyl, or heteroarylalkyl; P1a and P1b may optionally be joined to each other to form a spirocyclic or spiroheterocyclic ring contg. 0-6 oxygen, nitrogen, sulfur, or phosphorus atoms; P1' = H, (un)substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkylalkyl, heterocycl, heterocyclalkyl, aryl, arylalkyl, heteroaryl, or heteroarylalkyl] having HCV protease inhibitory activity are disclosed. Thus, peptide II was prep'd. via peptide coupling in soln. and showed Ki = 1-100 nM for inhibition of HCV protease.

IT 149885-80-3, NS3-NS4A protease

RL: BSU (Biological study, unclassified); BIOL (Biological study) (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 149885-80-3 HCPLUS

CN Proteinase, polyprotein-processing, NS3 (9CI) (CA INDEX NAME)

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

IT 393519-93-2P 393520-05-3P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses) (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393519-93-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

 $\equiv \text{CH}_2$


RN 393520-05-3 HCPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

08/08/2003

PAGE 1-A



PAGE 1-B

 $\approx \text{CH}_2$

IT 393519-95-4P 393519-97-6P 393520-00-8P
 393520-02-0P 393520-03-1P 393520-07-5P
 393520-09-7P 393520-11-1P 393520-13-3P
 393520-15-5P 393520-17-7P 393520-19-9P
 393520-21-3P 393520-23-5P 393520-25-7P
 393520-27-9P 393520-29-1P 393520-31-5P
 393520-33-7P 393520-35-9P 393520-37-1P
 393520-49-5P 393520-51-9P 393520-53-1P
 393520-55-3P 393520-57-5P 393520-59-7P
 393520-61-1P 393520-63-3P 393520-65-5P
 393520-67-7P 393520-69-9P 393520-70-2P
 393520-72-4P 393520-74-6P 393520-76-8P

393520-79-1P 393520-81-5P 393520-83-7P
 393520-85-9P 393520-87-1P 393520-89-3P
 393520-91-7P 393520-93-9P 393520-95-1P
 393520-97-3P 393520-99-5P 393521-01-2P
 393521-03-4P 393521-05-6P 393521-07-8P
 393521-09-0P 393521-11-4P 393521-13-6P
 393521-15-8P 393521-17-0P 393521-19-2P
 393521-21-6P 393521-23-8P 393521-25-0P
 393521-27-2P 393521-29-4P 393521-31-8P
 393521-33-0P 393521-35-2P 393521-37-4P
 393521-39-6P 393521-41-0P 393521-43-2P
 393521-45-4P 393521-47-6P 393521-49-8P
 393521-51-2P 393521-53-4P 393521-55-6P
 393521-57-8P 393521-59-0P 393521-61-4P
 393521-65-8P 393521-67-0P 393521-69-2P
 393521-72-7P 393521-74-9P 393521-77-2P
 393521-79-4P 393521-81-8P 393521-82-9P
 393521-84-1P 393521-91-0P 393521-94-3P
 393521-98-7P 393522-01-5P 393522-04-8P
 393522-09-3P 393522-12-8P 393522-14-0P
 393522-17-3P 393522-20-8P 393522-22-0P
 393522-24-2P 393522-26-4P 393522-28-6P
 393522-30-0P 393522-32-2P 393522-34-4P
 393522-36-6P 393522-39-9P 393522-42-4P
 393522-44-6P 393522-46-8P 393522-48-0P
 393522-50-4P 393522-52-6P 393522-55-9P
 393522-59-3P 393522-62-8P 393522-65-1P
 393522-68-4P 393522-71-9P 393522-74-2P
 393522-76-4P 393522-79-7P 393522-81-1P
 393522-84-4P 393522-87-7P 393522-90-2P
 393522-93-5P 393522-96-8P 393522-99-1P
 393523-02-9P 393523-04-1P 393523-06-3P
 393523-09-6P 393523-12-1P 393523-15-4P
 393523-18-7P 393523-21-2P 393523-24-5P
 393523-27-8P 393523-29-0P 393523-31-4P
 393523-33-6P 393523-35-8P 393523-37-0P
 393523-39-2P 393523-41-6P 393523-43-8P
 393523-45-0P 393523-47-2P 393523-49-4P
 393523-51-8P 393523-53-0P 393523-55-2P
 393523-57-4P 393523-59-6P 393523-60-9P
 393523-62-1P 393523-64-3P 393523-65-4P
 393523-67-6P 393523-69-8P 393523-71-2P
 393523-73-4P 393523-75-6P 393523-77-8P
 393523-79-0P 393523-81-4P 393523-84-7P
 393523-86-9P 393523-89-2P 393523-92-7P
 393523-94-9P 393523-95-0P 393523-97-2P
 393523-99-4P 393524-00-0P 393524-02-2P
 393524-07-7P 393524-09-9P 393524-12-4P
 394203-31-7P 394203-32-8P 394203-33-9P
 394203-34-0P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 393519-95-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393519-97-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-1-amino-.alpha.-oxocyclopentaneacetyl-, 7-(2-propenyl) ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393520-00-8 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-(oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-02-0 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-03-1 HCPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propenyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-07-5 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(propylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-09-7 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(propylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-11-1 HCAPLUS

CN L-Prolineamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[(methyl-2-propenylamino)oxoacetyl]butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-13-3 HCAPLUS



CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-4-[(1,1-dimethylethoxy)carbonyl]-2-piperazinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393520-15-5 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propynylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-17-7 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propynylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-19-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl)-7-(2-propynyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\text{---C}\equiv\text{CH}$

RN 393520-21-3 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(2-propynyl) ester (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 393520-23-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[(3-carboxypropyl)amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-25-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[(4-ethoxy-4-oxobutyl)amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-27-9 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[[4-ethoxy-4-oxobutyl]amino]oxoacetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-29-1 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[[3-carboxypropyl]amino]oxoacetyl]butyl]-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-31-5 HCPLUS

CN L-Methioninamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-(ethoxyoxoacetyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.



RN 393520-33-7 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[[(phenylmethoxy)carbonyl]amino]-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Mondesi 09/909,012

08/08/2003

PAGE 1-A



PAGE 1-B

$\approx \text{CH}_2$


RN 393520-35-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-2-piperazinecarbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.

08/08/2003

PAGE 1-A




PAGE 1-B

 $\text{--CO}_2\text{H}$ 

RN 393520-37-1 HCPLUS

CN L-Serinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-methyl-O-(phenylmethyl)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.




Mondesi 09/909,012

08/08/2003

RN 393520-49-5 HCPLUS


CN L-Serinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-methyl-O-(phenylmethyl)-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



PAGE 1-B


— NHMe



RN 393520-51-9 HCPLUS

CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-53-1 HCAPLUS

CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-55-3 HCAPLUS

CN .beta.-Alanine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-57-5 HCPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-59-7 HCPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-61-1 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-O-(1,1-dimethylethyl)-, 1,2-bis(1,1-dimethylethyl) 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-63-3 HCAPLUS

CN L-Serine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-O-(1,1-dimethylethyl)-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-65-5 HCAPLUS


CN 2-Azetidinecarboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 393520-67-7 HCAPLUS


CN 2-Azetidinecarboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (2S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B'



RN 393520-69-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-4-[(1,1-dimethylethoxy)carbonyl]-2-piperazinecarbonyl-3-amino-2-oxohexanoyl-


Mondesi 09/909,012

08/08/2003

, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

-OBu-t

RN 393520-70-2 HCAPLUS

CN L-Proline, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-72-4 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, 2-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-74-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(phenylmethoxy)carbonyl]amino]-L-prolyl-3-amino-2-oxohexanoyl-2-(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-76-8 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-79-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(phenylmethoxy)carbonylamino]-L-prolyl-3-amino-2-oxohexanoyl-7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-81-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(1,1-dimethylethoxy)-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 $\equiv \text{CH}_2$

RN 393520-83-7 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[[(1,1-dimethylethyl)dimethylsilyl]oxy]-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\equiv \text{CH}_2$

RN 393520-85-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-hydroxy-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393520-87-1 HCPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester, (8S)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393520-89-3 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, 2-(1,1-dimethylethyl) ester, (8S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-91-7 HCAPLUS

CN 1,4-Dithia-7-azaspiro[4.4]nonane-8-carboxamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, (8S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393520-93-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(3S)-3-amino-.alpha.,2-dioxo-.beta.-propyl-1-pyrrolidinepropanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OBu-t

RN 393520-95-1 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(3S)-3-amino-.alpha.,2-dioxo-.beta.-propyl-1-pyrrolidinepropanoyl-, 6-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393520-97-3 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393520-99-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-01-2 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-isoleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-03-4 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-2-methyl-1-[(4R)-4-[[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]propyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-05-6 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-2-methyl-1-[(4R)-4-[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-07-8 HCAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-N-[(1S)-1-[(4R)-1,1-dioxido-4-[[1-[oxo(2-propenylamino)acetyl]butyl]amino]carbonyl]-3-thiazolidinyl]carbonyl]-2-methylpropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-09-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\equiv \text{CH}_2$

RN 393521-11-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-13-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-15-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-17-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 393521-19-2 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 393521-21-6 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 393521-23-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S,3aS,7aS)-octahydro-1H-indole-2-carbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

08/08/2003

PAGE 1-A



PAGE 1-B


 $\text{CH}_2=\text{}$

RN 393521-25-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 $\text{--CO}_2\text{H}$

RN 393521-27-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 --OBu-t

RN 393521-29-4 HCPLUS



CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(5R)-5-phenyl-L-prolyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393521-31-8 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-methyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-33-0 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-methyl-L-valyl-L-valyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-35-2 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-5-methyl-L-norleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-37-4 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-5-methyl-L-norleucyl-N-[1-[oxo(2-propenylamino)acetyl]butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-39-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isouquinolinecarbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-41-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-43-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(1S)-1,2,3,4-tetrahydro-1-isoquinolinecarbonyl-3-amino-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-45-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-47-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-49-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-cyclohexyl-L-alanyl-L-prolyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-51-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S,5S)-5-amino-1,2,4,5,6,7-hexahydro-4-oxoazepino[3,2,1-hi]indole-2-carbonyl-3-amino-2-oxohexanoyl-, 6-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-53-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(2S)-2-piperidinocarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




Mondesi 09/909,012

08/08/2003

PAGE 1-B

-OBu-t




RN 393521-55-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidin carbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethyl ethyl) 7-propyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 OBu-t

RN 393521-57-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 7-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-59-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-61-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(2S)-2-piperidinecarbonyl-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-65-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-propyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-67-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-69-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

08/08/2003

Absolute stereochemistry.




RN 393521-72-7 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-oxohexanoyl-(9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393521-74-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxoheptanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393521-77-2 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valylglycyl-(3S)-3-amino-2-oxoheptanoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393521-79-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-81-8 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-(2-phenylethyl)-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-82-9 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(aminoxyoacetyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-84-1 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(carboxycarbonyl)butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-91-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-94-3 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-, 7-(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393521-98-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[(1-methylethyl)amino]oxoacetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-01-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexenoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-04-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexenoyl-, 7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-09-3 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-2-propynyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-12-8 HCPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-14-0 HCPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl-N-propyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-17-3 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxo-5-hexynoyl-, 7-(2-propenyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-20-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-phenylglycyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


 $\text{--CO}_2\text{H}$

RN 393522-22-0 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-methylglycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




RN 393522-24-2 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(2S)-2-azetidinecarbonyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 393522-26-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(carboxymethoxy)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-28-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-(2S)-2-cyclohexylglycyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-30-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-phenylalanyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-32-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-isoleucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-34-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-2-piperidinecarbonyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\text{--CO}_2\text{H}$

RN 393522-36-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(3S)-1,2,3,4-tetrahydro-3-isoquinolinecarbonyl-(3S)-3-amino-2-oxohexanoyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-39-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-thiazolidinecarbonyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-42-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S-methyl-L-cysteinyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-44-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-3-(methylsulfonyl)-L-alanyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-46-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S-(carboxymethyl)-L-cysteinyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-48-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-S,S-dioxido-L-methionyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-50-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3R)-3-amino-4-(methylthio)-2-oxobutanoyl-, 7-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-52-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[(phenoxy carbonyl) amino] methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-55-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[(benzoylamino)methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-59-3 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393522-62-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[[3-phenoxybenzoyl)amino]methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-65-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(phenylsulfonyl)amino]methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-68-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-71-9 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-[[[(phenylamino)carbonyl]amino]methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-74-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(benzoylamino)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393522-76-4 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(4-methoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-

Mondesi 09/909,012

08/08/2003

(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-79-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(4-phenoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-81-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(3-phenoxybenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-84-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(phenylmethyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-87-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(4-methoxyphenyl)methyl]-L-prolyl-(3S)-3-amino-2-oxohexanoyl-(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393522-90-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-(2-propenyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393522-93-5 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[1,3-benzodioxol-5-ylcarbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A



RN 393522-96-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(4-fluorobenzoyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393522-99-1 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(2-methylpropoxy)carbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-02-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(phenylsulfonyl)amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-04-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(4-methoxyphenyl)sulfonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-06-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[(phenylamino)carbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-09-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-[[[(4-methoxyphenyl)amino]carbonyl]amino]-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-12-1 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-.alpha.-aspartyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-15-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-.alpha.-glutamyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-18-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-phenylalanyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-21-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4R)-4-amino-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-24-5 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-(carboxymethyl)-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-27-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-seryl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-29-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-alanyl-L-valyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-31-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-histidyl-L-valyl-L-prolyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-33-6 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-asparaginyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-35-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(4S)-4-phenyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-37-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-(3S)-3-methyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-39-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-(2-carboxyethyl)glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-41-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[2-(3,4-dimethoxyphenyl)ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-43-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(4S)-4-amino-4-carboxybutyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-45-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-ornithyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-47-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-D-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-49-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-allothreonyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-51-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-.beta.-phenyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-53-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-(2S)-2,4-diaminobutanoyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-55-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-aspartyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-57-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-59-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-threonyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-60-9 HCPLUS

CN Glycine, N-acetyl-L-alanyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-62-1 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-leucyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-64-3 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-[2-(benzoylamino)ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-65-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[2-[(3-phenoxybenzoyl)amino]ethyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393523-67-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[3-(benzoylamino)propyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-69-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(5S)-5-amino-5-carboxypentyl]glycyl-(3S)-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393523-71-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-(1-naphthalenyl)-L-alanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-73-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-3-(2-naphthalenyl)-L-alanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-75-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-homoseryl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-77-8 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-.alpha.-methyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-79-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-leucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-81-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-3-methyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-84-7 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-seryl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-86-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-threonyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-89-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-norleucyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-92-7 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-.beta.-phenyl-L-phenylalanyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-94-9 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-O-methyl-L-seryl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-95-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-asparaginyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-97-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-glutaminyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393523-99-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-phenylalanyl-L-valyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-00-0 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-methionyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-02-2 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-cysteinyl-L-prolyl-(3S)-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-07-7 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-09-9 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-
isoleucyl-N-[(1S)-1-[oxo(2-propenylamino)acetyl]butyl]- (9CI) (CA INDEX
NAME)

Absolute stereochemistry.




RN 393524-12-4 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-5-methyl-2-oxohexanoyl-, 7-(2-propenyl) ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

08/08/2003




RN 394203-31-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-cyclohexylalanyl-3-amino-2-oxohexanoyl-, 2-propenyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



RN 394203-32-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-cyclohexylalanyl-3-amino-2-oxohexanoyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 394203-33-9 HCPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-oxohexanoylglycyl-2-phenyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

08/08/2003




RN 394203-34-0 HCPLUS


CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-3-(methylsulfonyl)alanyl-3-amino-2-oxohexanoyl- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




IT 91-00-9, Diphenylmethylamine 98-79-3, L-Pyroglutamic acid 106-95-6, Allyl bromide, reactions 109-80-8, 1,3-Propanedithiol 618-27-9 870-46-2, tert-Butyl carbazate 2746-25-0, p-Methoxybenzyl bromide 2999-46-4, Ethyl isocyanoacetate 5437-45-6, Benzyl bromoacetate 7188-38-7, tert-Butyl isocyanide 13726-69-7 53308-95-5 64187-48-0 71989-28-1 138021-87-1 166196-06-1 216378-84-6

RL: RCT (Reactant); RACT (Reactant or reagent)
(prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 91-00-9 HCAPLUS


CN Benzenemethanamine, .alpha.-phenyl- (9CI) (CA INDEX NAME)



RN 98-79-3 HCAPLUS


CN L-Proline, 5-oxo- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 106-95-6 HCAPLUS

CN 1-Propene, 3-bromo- (9CI) (CA INDEX NAME)




RN 109-80-8 HCAPLUS

CN 1,3-Propanedithiol (6CI, 7CI, 8CI, 9CI) (CA INDEX NAME)




RN 618-27-9 HCAPLUS
 CN L-Proline, 4-hydroxy-, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).




RN 870-46-2 HCAPLUS
 CN Hydrazinecarboxylic acid, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 2746-25-0 HCAPLUS
 CN Benzene, 1-(bromomethyl)-4-methoxy- (9CI) (CA INDEX NAME)




RN 2999-46-4 HCAPLUS
 CN Acetic acid, isocyano-, ethyl ester (7CI, 8CI, 9CI) (CA INDEX NAME)



RN 5437-45-6 HCAPLUS
 CN Acetic acid, bromo-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 7188-38-7 HCAPLUS
 CN Propane, 2-isocyano-2-methyl- (9CI) (CA INDEX NAME)




Mondesi 09/909,012

08/08/2003

RN 13726-69-7 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl) ester,
(2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 53308-95-5 HCPLUS

CN L-Norvaline, N-[(1,1-dimethylethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 64187-48-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 2-methyl 1-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 71989-28-1 HCPLUS

CN L-Methionine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 138021-87-1 HCPLUS


CN L-Cysteine, N-[(9H-fluoren-9-ylmethoxy) carbonyl]-S-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 166196-06-1 HCPLUS


CN Hexanoic acid, 3-[(1,1-dimethylethoxy) carbonyl]amino]-2-hydroxy- (9CI) (CA INDEX NAME)



RN 216378-84-6 HCPLUS

CN L-Cysteine, N-[(1,1-dimethylethoxy) carbonyl]-S-methyl-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 16217-15-5P 35418-16-7P 58948-98-4P
 63307-62-0P 76203-43-5P 91229-91-3P
 113490-83-8P 116611-55-3P 127949-74-0P
 132622-88-9P 132622-90-3P 132622-91-4P
 132622-94-7P 143935-63-1P 150908-38-6P
 153074-95-4P 160801-74-1P 160806-17-7P
 163437-14-7P 176486-63-8P 185304-19-2P
 189215-88-1P 189215-89-2P 189215-90-5P
 224645-82-3P 224645-88-9P 237421-53-3P
 244132-29-4P 273221-98-0P 276888-16-5P
 276888-17-6P 276888-55-2P 276888-56-3P
 393513-18-3P 393524-17-9P 393524-22-6P
 393524-24-8P 393524-25-9P 393524-27-1P
 393524-29-3P 393524-31-7P 393524-36-2P
 393524-38-4P 393524-40-8P 393524-42-0P
 393524-47-5P 393524-49-7P 393524-52-2P
 393524-55-5P 393524-57-7P 393524-63-5P
 393524-67-9P 393524-68-0P 393524-70-4P
 393524-72-6P 393524-75-9P 393524-83-9P
 393524-95-3P 393525-00-3P 393525-03-6P
 393525-07-0P 393525-09-2P 393525-11-6P
 393525-16-1P 393525-18-3P 393525-21-8P
 393525-23-0P 393525-25-2P 393525-27-4P
 393525-29-6P 393525-31-0P 393525-36-5P
 393525-37-6P 393525-38-7P 393525-39-8P
 393525-40-1P 393525-41-2P 393525-42-3P
 393525-43-4P 393525-44-5P 393525-45-6P
 394203-35-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (prepn. of novel peptides as NS3-serine protease inhibitors of hepatitis C virus)

RN 16217-15-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-oxo-, 2-methyl 1-(phenylmethyl) ester,
 (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 35418-16-7 HCPLUS


CN L-Proline, 5-oxo-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 58948-98-4 HCPLUS


CN Acetic acid, isocyano-, potassium salt (9CI) (CA INDEX NAME)



● K


RN 63307-62-0 HCPLUS

CN 1H-Benzotriazole, 1-hydroxy-, ammonium salt (9CI) (CA INDEX NAME)

● NH₃

RN 76203-43-5 HCPLUS


CN Acetic acid, isocyano-, 2-propenyl ester (9CI) (CA INDEX NAME)



RN 91229-91-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-, bis(1,1-dimethylethyl) ester, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 113490-83-8 HCPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid, 3-methyl
2-(phenylmethyl) ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 116611-55-3 HCPLUS

CN Carbamic acid, [(1S)-1-(hydroxymethyl)butyl]-, 1,1-dimethylethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 127949-74-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-(phenylmethyl)-,
bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 132622-88-9 HCPLUS

CN L-Proline, 4-hydroxy-, phenylmethyl ester, (4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132622-90-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-hydroxy-, 1-(1,1-dimethylethyl)
2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 132622-91-4 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[{(methylsulfonyl)oxy]-,
1-(1,1-dimethylethyl) 2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX
NAME)


Absolute stereochemistry.



RN 132622-94-7 HCPLUS


CN 1,2-Pyrrolidinedicarboxylic acid, 4-cyano-, 1-(1,1-dimethylethyl)
2-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 143935-63-1 HCAPLUS
 CN L-Alanine, N-[(1,1-dimethylethoxy)carbonyl]-3-(methylsulfonyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 150908-38-6 HCAPLUS
 CN Hydrazinecarboxylic acid, 2-[(diphenylmethyl)amino]carbonyl-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)




RN 153074-95-4 HCAPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-(phenylmethyl)-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



RN 160801-74-1 HCAPLUS
 CN Carbamic acid, [(1S)-1-formylbutyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 160806-17-7 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-[2-oxo-2-(phenylmethoxy)ethyl]-, bis(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 163437-14-7 HCAPLUS

CN Butanoic acid, 2-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-4-(methylsulfonyl)-, (2S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 176486-63-8 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 185304-19-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 1-(1,1-dimethylethyl)
2-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-88-1 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[{(methylsulfonyl)oxy]-, 2-methyl
1-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-89-2 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-azido-, 2-methyl 1-(phenylmethyl)
ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 189215-90-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-, 2-methyl 1-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224645-82-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-(2-propenyl)-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 224645-88-9 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[2-oxo-2-(phenylmethoxy)ethyl]-, 1-(1,1-dimethylethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 237421-53-3 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 5-oxo-4-(2-propenyl)-,
bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 244132-29-4 HCPLUS

CN L-Alanine, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-3-(methylsulfonyl)- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 273221-98-0 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(9H-fluoren-9-
ylmethoxy)carbonyl]amino]methyl]-, 1-(1,1-dimethylethyl) ester, (2S,4S)-
(9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




RN 276888-16-5 HCPLUS

Mondesi 09/909,012

08/08/2003

CN L-Norvaline, N-[(9H-fluoren-9-ylmethoxy)carbonyl]-, methyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 276888-17-6 HCPLUS

CN Carbamic acid, [(1S)-1-(hydroxymethyl)butyl]-, 9H-fluoren-9-ylmethyl ester
(9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 276888-55-2 HCPLUS

CN Carbamic acid, [(1S)-1-formylbutyl]-, 9H-fluoren-9-ylmethyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 276888-56-3 HCPLUS

CN Glycine, N-[(3S)-3-[(9H-fluoren-9-ylmethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl-, 2-propenyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393513-18-3 HCAPLUS

CN L-Proline, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-17-9 HCAPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[[[(1,1-dimethylethoxy)carbonyl]amino]-, 1-(phenylmethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-22-6 HCAPLUS

CN L-Glutamic acid, N-acetyl-L-.alpha.-glutamyl-, 1,25-bis(1,1-dimethylethyl) 21-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-24-8 HCPLUS

CN L-Glutamic acid, N-acetyl-L-.alpha.-glutamyl-, 1,25-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-25-9 HCPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-, 1,2-bis(1,1-dimethylethyl) 3-methyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-27-1 HCPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 393524-29-3 HCPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-,
1,2-bis(1,1-dimethylethyl) 4-(phenylmethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-31-7 HCPLUS

CN L-Valine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-,
1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-36-2 HCPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid,
2-(1,1-dimethylethyl) 3-methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-38-4 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-2,3-dicarboxylic acid,
2-(1,1-dimethylethyl) ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-40-8 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, methyl ester,
hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 393524-42-0 HCAPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]acetyl-, methyl ester, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-47-5 HCPLUS

CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-[cyclohexyl[(1,1-dimethylethoxy)carbonyl]amino]acetyl]-, (3S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-49-7 HCPLUS


CN 6,10-Dithia-2-azaspiro[4.5]decane-3-carboxylic acid, 2-(aminocyclohexylacetyl)-, methyl ester, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 393524-52-2 HCAPLUS


CN Glycine, N-[3-[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-oxohexyl-
, 2-propenyl ester (9CI) (CA INDEX NAME)

RN 393524-55-5 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-
cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-
2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A




RN 393524-57-7 HCAPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-
cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-

2-oxohexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-63-5 HCPLUS

CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(4-methoxyphenyl)methyl]-5-oxo-, bis(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-67-9 HCPLUS

CN L-Proline, 4-(phenylmethyl)-, (4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393524-68-0 HCPLUS


CN L-Proline, 4-[(4-methoxyphenyl)methyl]-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393524-70-4 HCPLUS
 CN L-Proline, 4-(2-propenyl)-, (4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393524-72-6 HCPLUS
 CN 3-Pyrrolidineacetic acid, 5-carboxy-, .alpha.- (phenylmethyl) ester, (3S,5S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393524-75-9 HCPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-[(4-methoxyphenyl)methyl]-, 1-(1,1-dimethylethyl) ester, (2S,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393524-83-9 HCPLUS
 CN 1,2-Pyrrolidinedicarboxylic acid, 4-chloro-, 1-(1,1-dimethylethyl)-2-(phenylmethyl) ester, (2S,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393524-95-3 HCAPLUS


CN L-Proline, 4-[[[(9H-fluoren-9-ylmethoxy)carbonyl]amino]methyl]-, (4R)-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 393524-94-2

CMF C21 H22 N2 O4


Absolute stereochemistry.



CM 2

CRN 76-05-1


CMF C2 H F3 O2



RN 393525-00-3 HCAPLUS

CN Carbamic acid, [(1S)-1-[2-[(1,1-dimethylethyl)amino]-1-hydroxy-2-oxoethyl]butyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-03-6 HCAPLUS

CN Hexanoic acid, 3-[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-, ethyl ester, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-07-0 HCAPLUS

CN Hydrazinecarboxamide, N-(diphenylmethyl)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)

CM 1

CRN 150908-39-7


CMF C14 H15 N3 O



CM 2

CRN 104-15-4

CMF C7 H8 O3 S




RN 393525-09-2 HCAPLUS

CN Hexanoic acid, 3-[(1,1-dimethylethoxy)carbonyl]amino]-2-


[[(diphenylmethyl)amino]carbonyl]hydrazone]-, ethyl ester, (3S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry unknown.




RN 393525-11-6 HCAPLUS
 CN Hexanoic acid, 3-[(1,1-dimethylethoxy)carbonyl]amino]-2-
 [[(diphenylmethyl)amino]carbonyl]hydrazone]-, (2Z,3S)- (9CI) (CA INDEX
 NAME)

Absolute stereochemistry.
Double bond geometry as shown.




RN 393525-16-1 HCAPLUS
 CN Glycine, N-[(3S)-3-[(1,1-dimethylethoxy)carbonyl]amino]-2-hydroxy-1-
 oxohexyl]-, ethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 393525-18-3 HCAPLUS
 CN Glycine, N-[(3S)-3-amino-2-hydroxy-1-oxohexyl]-, ethyl ester,
 monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 393525-21-8 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl)7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-23-0 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl)7-ethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-25-2 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-27-4 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-29-6 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2S,3S)-3-amino-2-hydroxyhexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-31-0 HCAPLUS

CN Glycinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(2R,3S)-3-amino-2-hydroxyhexanoyl-N-2-propenyl-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

 $\equiv \text{CH}_2$

RN 393525-36-5 HCPLUS

CN Glycine, N-[(3S)-3-amino-2-hydroxy-1-oxohexyl]-, 2-propenyl ester (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 393525-37-6 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-L-prolyl-(3S)-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl)7-(2-propenyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-38-7 HCPLUS

CN Hexanamide, 3-amino-2-hydroxy-, monohydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 393525-39-8 HCPLUS


CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-N-[(1S)-1-(2-amino-1-hydroxy-2-oxoethyl)butyl]-,

Mondesi 09/909,012

08/08/2003

bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-40-1 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(amino oxoacetyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-41-2 HCPLUS

CN Hexanoic acid, 3-amino-2-hydroxy-, ethyl ester, hydrochloride, (3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 393525-42-3 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(2-ethoxy-1-hydroxy-2-oxoethyl)butyl]-, bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-43-4 HCPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(carboxyhydroxymethyl)butyl]-, 1,2-bis(1,1-dimethylethyl) ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 393525-44-5 HCAPLUS

CN L-Prolinamide, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-L-valyl-N-[(1S)-1-(carboxyhydroxymethyl)butyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 393525-45-6 HCAPLUS

CN Hexanoic acid, 3-[[[(1,1-dimethylethoxy)carbonyl]amino]-2-[[[(diphenylmethyl)amino]carbonyl]hydrazone]-, (2E,3S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Double bond geometry as shown.




RN 394203-35-1 HCPLUS

CN Glycine, N-acetyl-L-.alpha.-glutamyl-L-.alpha.-glutamyl-L-valyl-2-cyclohexylglycyl-(8S)-1,4-dithia-7-azaspiro[4.4]nonane-8-carbonyl-3-amino-2-hydroxyhexanoyl-, 1,2-bis(1,1-dimethylethyl) 7-(2-propenyl) ester (9CI)
(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

